Original Research J Clin Psychiatry January 2010

A Double-Blind, Placebo-Controlled Study of Quetiapine and Lithium Monotherapy in Adults in the Acute Phase of Bipolar Depression (EMBOLDEN I)

JCP 2010;71(2):10.4088/JCP.08m04995gre

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2010;71(2):10.4088/JCP.08m04995gre Clinical Summary Acute bipolar depression drives much of the morbidity and disability in bipolar disorder, yet first-line treatment choices still often include agents with limited direct evidence for antidepressant efficacy. This trial matters because it directly compares quetiapine monotherapy, lithium monotherapy, and placebo in adults with bipolar depression and shows which option produced measurable symptom relief over 8 weeks. FAQ Did quetiapine work better than placebo for acute bipolar depression in this study? 10 questions
Key Takeaways Quetiapine separated from placebo by week 1 on both MADRS and HARS, supporting its use when early improvement in depressive and anxiety symptoms is clinically important during an acute bipolar depression episode. 6 takeaways Clinical Guide How should clinicians initiate quetiapine monotherapy for adults with acute bipolar depression based on the EMBOLDEN I trial? 7 steps Clinical Guide How should clinicians monitor early response and key safety outcomes during 8 weeks of monotherapy for acute bipolar depression based on EMBOLDEN I? 8 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe